Ranked #5,008 of 8,699 institutional investors
Squadron Capital Management LLC
Oak Brook, IL
$299M
US stock portfolio at live prices · today +$1.3M (+0.45%)
Market closed. Prices as of Nov 20, 8:41 AM ET
- Value at quarter end (Q3 2026)
- $337M
- Change from Q2 2026
- +$45.3M (+15.52%)
- Positions
- 29 · 11 new, 10 sold out
- Filed
- Nov 16, 2026
Not counted in the ranking: call options on $61.0M of stock. $30.9M of holdings we could not match to a US listing are included at their reported quarter-end value.
Holdings
Q3 2026 13F, live pricesSLN 13.8%KOD 13.8%COGT 8.49%CCCC 7.61%EWTX 5.86%
| Stock | Shares | Value, live | % of portfolio | vs Q2 2026 |
|---|---|---|---|---|
| SLN Silence Therapeutics plc | 2,085,000 | $41.3M | 13.8% | New |
| KOD Kodiak Sciences Inc. | 420,000 | $41.1M | 13.8% | Reduced −16% |
| COGT Cogent Biosciences, Inc. | 915,000 | $25.4M | 8.49% | Added +6% |
| CCCC C4 Therapeutics, Inc. | 9,318,683 | $22.7M | 7.61% | Added +29% |
| EWTX Edgewise Therapeutics, Inc. | 425,000 | $17.5M | 5.86% | Added +47% |
| RLAY Relay Therapeutics, Inc. | 785,000 | $12.5M | 4.18% | Reduced −19% |
| RLMD Relmada Therapeutics, Inc. | 3,500,000 | $10.9M | 3.64% | Reduced −52% |
| DFTX Definium Therapeutics, Inc. | 340,000 | $10.0M | 3.35% | Added +300% |
| ZNTL Zentalis Pharmaceuticals, Inc. | 6,827,905 | $9.3M | 3.11% | Added +85% |
| IVA Inventiva S.A. | 2,400,000 | $8.3M | 2.77% | Reduced −1% |
| VERA Vera Therapeutics, Inc. | 305,000 | $8.2M | 2.73% | New |
| ORIC ORIC Pharmaceuticals, Inc. | 1,000,000 | $7.7M | 2.58% | New |
| ANL Adlai Nortye Group Ltd. | 764,876 | $6.9M | 2.32% | Unchanged |
| ASMB Assembly Biosciences, Inc. | 225,000 | $5.1M | 1.69% | Added +41% |
| ACRS Aclaris Therapeutics, Inc. | 1,200,000 | $4.2M | 1.41% | New |
| IRLA IRulya Therapeutics Inc. | 90,000 | $3.6M | 1.20% | Added +123% |
| SVRA Savara Inc. | 675,000 | $3.5M | 1.18% | New |
| TNGX Tango Therapeutics, Inc. | 150,000 | $3.4M | 1.14% | New |
| ADAG Adagene Inc. | 1,616,618 | $3.2M | 1.09% | Added +29% |
| YARW Yarrow Bioscience, Inc. | 225,000 | $3.2M | 1.07% | New |
| AVTX Avalo Therapeutics, Inc. | 450,000 | $3.0M | 1.02% | New |
| CTNM Contineum Therapeutics, Inc. | 323,570 | $2.9M | 0.98% | Added +24% |
| PALI Palisade Bio, Inc. | 3,000,000 | $2.8M | 0.93% | Unchanged |
| IKT Inhibikase Therapeutics, Inc. | 2,000,000 | $2.6M | 0.87% | Reduced −33% |
| PEPG PepGen Inc. | 600,000 | $2.4M | 0.79% | New |
| JANX Janux Therapeutics, Inc. | 215,000 | $2.2M | 0.74% | New |
| ALXO ALX Oncology Holdings Inc. | 1,400,000 | $1.4M | 0.48% | New |
| SCYX SCYNEXIS, Inc. | 515,045 | $1.3M | 0.45% | Reduced −32% |
| LPCN Lipocine Inc. | 810,000 | $1.2M | 0.41% | Unchanged |
Sold out in Q3 2026
| Stock | Shares held at Q2 2026 | Worth today |
|---|---|---|
| MAZE Maze Therapeutics, Inc. | 335,000 | $10.9M |
| ELVN Enliven Therapeutics, Inc. | 160,000 | $7.4M |
| CMPS COMPASS Pathways plc | 300,000 | $2.6M |
| RZLT Rezolute, Inc. | 403,410 | $1.7M |
| PMN ProMIS Neurosciences, Inc. | 324,977 | $1.0M |
| BIOA BioAge Labs, Inc. | 155,000 | $730K |
| KTTA Pasithea Therapeutics Corp. | 1,000,000 | $481K |
| NXTC NextCure, Inc. | 64,464 | $437K |
| CUE Cue Biopharma, Inc. | 50,000 | $225K |
| NMRA Neumora Therapeutics, Inc. | 100,000 | $35K |